Pharmacokinetic parameters of dabigatran, calculated from free dabigatran concentration/time data, following p.o. administration of 200 mg of [14C]dabigatran etexilate (2.8 MBq) or i.v. infusion of 5 mg of [14C]dabigatran (2.8 MBq) in healthy male volunteers (n = 5 per treatment)
Results are presented as mean ± S.D.
5 mg of [14C]Dabigatran i.v. | 200 mg of [14C]Dabigatran Etexilate p.o. | |
|---|---|---|
| Cmax (ng/ml) | 187.0 ± 37.4 | 145.0 ± 45.2 |
| Tmax (h) | 0.5 ± 0.02 | 1.15 ± 0.49 |
| AUC0-24 (ng · h/ml) | 490.0 ± 55.5 | 839.0 ± 209.0 |
| AUC0-∞ (ng · h/ml) | 526.0 ± 63.0 | 930.0 ± 232.0 |
| t1/2 (h) | 7.31 ± 0.74 | 9.4 ± 2.1 |
| Cltot (ml/min) | 155.0 ± 20.4 | N.A. |
| Cltot/F (ml/min) | N.A. | 3020.0 ± 614.0 |
| Vss (1) | 68.6 ± 9.76 | N.A. |
| Vz/F (1) | N.A. | 2400 ± 513 |
| MRT (h) | 7.4 ± 0.85 | 9.7 ± 1.7 |
| F (%) | N.A. | 5.97 |
N.A., not applicable.